Brainomix Stroke Al Software Hailed asRevolutionary, Helping More Patients Fully Recover
NEWS PROVIDED BYBrainomix03 Sep, 2025, 12:34 GMT
OXFORD, England and CHICAGO, Sept. 3, 2025 /PRNewswire/ . Brainomix, a global leader and pioneer of Al-powered imaging toolsin stroke and lung
fibrosis, has garnered widespread media attention' this week following a renewed focus on the impact of itsBrainomix 360 Stroke technology to improve
recovery rates for stroke patients.
A study published by the Royal Berkshire Hospitaldemonstrated that Brainomix software tripled thenumber of stroke patients achieving
functionalindependence, from 16% to 48%. Additional data fromthe largest real-world evaluation of stroke Al imagingshowed that Brainomix 360
Stroke was associated witha more than 50% increase in mechanicalthrombectomy, a life-changing stroke treatment.
Brainomix 360 Stroke is a comprehensive platformpowered by highly advanced Al algorithms, supportingclinicians by providing real-time interpretation
of brainscans to help guide treatment and transfer decisionsfor stroke patients in both specialist and generalhospitals.
*Brainomix 360 Stroke provides real-time interpretation of brain scans to help guide treatment and transfer decisions
for stroke patients
David Hargroves, the NHS Clinical Director for Stroke, sid: "This Al decision support technology is revolutionizing how we helppeople who have been
affected by stroke. lt is estimate?a patient loses around 2m brain cells a minute at the start of a stroke, whichis why quick diagnosis and treatment is so
critical. Al deision support software provides real-time interpretation of patients' brainscans-supporting expert doctors and other NHS staff tmake
faster treatment decisions.ix, said: "Brainomix is helping clinicians every day improve the level of careDr Michalis Papadakis, CEO and Co-Founder at
Brainonthey can deliver to stroke patients in the UK and worldwide. We are delighted to see a focus on the unique and powerful impact thatour
technology is having on patient outcomes, validatedby an expanding base of published, real-world evidence.
Brainomix is widely recognised as one of the UK's most slccessful Al healthcare companies, having developed its technology throughd a number of
successful partnerships with NHS England and The Healthcommercial scale up to market launch, and having secureInnovation Network.
Brainomix 360 Stroke has been deployed widely acrosse UK and Europe, where it is the established market leader, and in theUnited States, where it has
been validated by a number oworld-class stroke institutions and exhibiting a similar clinical impact onstroke care.
The Times, The Guardian, The Telegraph, The Daily Mail, The independent, The Sun, The Mirroi
Notes to Editors
About Brainomix
Brainomix specializes in the creation of Al-powered softvare solutions to enable precision medicine for better treatment decisions ine University of
Oxford, Brainomix is an expanding commercial-stage companystroke and lung fibrosis. With origins as a spinout from tlns in more than 20 countries. A
private company, backed by leadingwith offices in the UK, lreland and the USA, and operaticning imaging biomarkers and software solutions that have
been clinicallyhealthtech investors, Brainomix has innovated award-widuct, the Brainomix 360 stroke platform, provides clinicians with the mostadopted
in hundreds of hospitals worldwide. lts first procomprehensive stroke imaging solution, driving increasd treatment rates and improving functional
independence for patients.
To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook
Contacts
Jeff Wyrtzen, Chief Marketing Officer
jwyrtzen@brainomix.com
T +44 (0)1865 582730
Media Enguiries
Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585
lmage -https://mma.prnewswire.com/media/2763605/Brainomix 360 Stroke.jpg